drugset / Trial / NCT04843449
Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the effects of itraconazole (a strong inhibitor of cytochrome P450 3A (CYP3A)) and rifampicin (a strong inducer of CYP3A) on the pharmacokinetics of ASC40 in healthy volunteers.
Timeline
- Start
- 2021-04-04
- Primary completion
- 2021-05-06
- Completion
- 2021-05-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Denifanstat | Small molecule | 50 mg | Oral |
| Subject | Itraconazole | Small molecule | 200 mg | Oral |
| Subject | Rifampin | Small molecule | 600 mg | Oral |
Indications
No indication recorded.